Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bone Biologics Inc.

This article was originally published in Start Up

Executive Summary

Bone Biologics' protein for stimulating bone growth was originally isolated from areas of active bone growth in humans. Based on animal studies to date, the company's founders claim that its UCB-1, performs as well if not better than marketed BMPs because of its molecular specificity. The company plans to combine UCB-1 with a proprietary scaffold to create biological solutions to a number of bone disorders.

You may also be interested in...



CeraPedics LLC

It's truism in spine that 4% of patients rack up 75% in costs, and expensive BMP products, which are highly successful at enhancing fusion rates, are the "high octane" products for more difficult cases-high-risk patients or the obese, for example. The market needs a product for the majority of cases, believes the founder of CeraPedics LLC, and he believes his company has it in its P-15, a growth factor that's a small peptide.

US FDA Still Seeking Sponsor Cooperation For Oncology Label Updates

Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.

Oncology Drug Safety Is Key Focus In US FDA’s Generic Label Updates

US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.

Topics

Related Companies

UsernamePublicRestriction

Register

MT037424

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel